"RenovoRx, Inc. (NASDAQ: RNXT) has reported a shift from losses to profitability, driven by commercial revenue growth and positive interim data from its pivotal Phase III TIGeR-PaC trial. However, the company still faces risks associated with ongoing losses and the long-term nature of its oncology breakthroughs, reflected in a low sentiment score of 0.24."